IPCA Labs Q3 net profit up 67% at Rs 180 crore

IPCA Labs had received voluntary action indicated (VAI) classification from the United States Food and Drug Administration (USFDA) for its Ratlam, Madhya Pradesh manufacturing facility in October

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

IPCA Labs on February 14 reported a 66.8 percent year-on-year rise in consolidated net profit at Rs 179.88 crore in the October-December quarter.

The pharma company reported a net profit of Rs 107.84 crore in the year-ago period.

Revenue came in at Rs 2,052.86 crore, up 32 percent from Rs 1,546 crore year-ago quarter, the company said.

Consolidated EBITDA margin [before forex (gain)/loss, other income and exceptional items] at 16.12 percent in Q3 FY24 as against 15 percent in Q3 FY23. The EBITDA came in at Rs 332 crore in the October-December quarter against Rs 216 crore in the same period a year ago.

Indian formulations income was reported to be up 11  percent at Rs 779.61 crores. Exports income was up 1 percent at Rs 640.34 crores. Sales of Active Pharmaceutical Ingredients (API) were down 13 percent in the quarter.

Shares of the company reacted positively and were trading 2.06 percent higher at Rs 1184.60 at 1.47 pm on NSE.

(This is a developing story, please check back for updates.)